Pulmonary arterial hypertension – Page 2

Merck Advances with Winrevair: Positive Phase III Results in Severe Pulmonary Arterial Hypertension (PAH) Study

7 months ago talkbio0Tagged Cardiovascular system, Merck, Morbidity - disease rate, Mortality Vital Statistics, PAH, Phase III, Pulmonary arterial hypertension, Winrevair, ZENITH study

Merck, Winrevair, PAH, Phase III, ZENITH study, pulmonary arterial hypertension, cardiovascular drug, morbidity, mortality

Advancements in Pulmonary Hypertension and Interstitial Lung Disease: Emerging Therapies and Clinical Trial Designs

9 months ago talkbio0Tagged Clinical Trials, diagnostic tools, Lung Diseases, Interstitial, Pathogenesis, Phenotype, Pulmonary arterial hypertension, Pulmonary Hypertension

Pulmonary Hypertension (PH), Interstitial Lung Disease (ILD), Pulmonary Arterial Hypertension (PAH), Clinical Trials, Emerging Therapies, Pathogenesis, Phenotypes, Diagnostic Tools

Cereno’s CS1 Shows Promising Results in Reducing PAH Risks in Phase 2 Trial

9 months ago talkbio0Tagged Cereno, disease-modifying, Epigenetic modulation, HDAC9 gene, Inhibitor, Phase 2 trial, Pulmonary arterial hypertension, Science, SLAMF7 protein, human

Cereno Scientific, CS1, HDAC inhibitor, Pulmonary Arterial Hypertension (PAH), Phase 2 trial, Epigenetic modulation, CardioMEMS HF System, Disease-modifying treatment

Merck’s WINREVAIR Receives EU Approval for Pulmonary Arterial Hypertension Treatment

10 months ago talkbio0Tagged 4-aminohippuric acid, Approved, EU, Merck, Pulmonary arterial hypertension, Winrevair

WINREVAIR, Merck, EU Approval, Pulmonary Arterial Hypertension, PAH Treatment

Liquidia’s Yutrepia Receives Tentative FDA Approval Due to Tyvaso Exclusivity

11 months ago talkbio0Tagged 4-aminohippuric acid, exclusivity, Liquidia, PH-ILD, Pulmonary arterial hypertension, Tentative Approval, Tyvaso, United States Food and Drug Administration, YUTREPIA

Liquidia, Yutrepia, FDA, tentative approval, Tyvaso, exclusivity, pulmonary arterial hypertension, PAH, PH-ILD

FDA Grants Tentative Approval for YUTREPIA, a New Treatment for Pulmonary Arterial Hypertension and Pulmonary Hypertension Associated with Interstitial Lung Disease

11 months ago talkbio0Tagged Associated with, Lung Diseases, Interstitial, PH-ILD, Pulmonary arterial hypertension, Pulmonary Hypertension, regulatory exclusivity, Tentative Approval, Tyvaso, United States Food and Drug Administration, United Therapeutics, YUTREPIA

YUTREPIA, treprostinil, pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD), FDA tentative approval, regulatory exclusivity, United Therapeutics, Tyvaso

Aerovate Therapeutics’ Shares Plummet 93.3% After Disappointing IMPAHCT Study Results for AV-101 in Pulmonary Arterial Hypertension

1 year ago talkbio0Tagged 4-aminohippuric acid, Aerovate, AV-101, Biotech Stocks, Clinical Trials, Drug Formulation Process, imatinib, IMPAHCT, Inspiration function, Pulmonary arterial hypertension

Aerovate Therapeutics, AV-101, IMPAHCT Study, Pulmonary Arterial Hypertension, PAH, Imatinib, Inhaled Formulation, Biotech Stocks, Clinical Trials